American Society of Hematology (ASH)

The American Society of Hematology (ASH) is a professional organization representing hematologists. It was founded in 1958. Its annual meeting is held in December of every year and has attracted more than 30,000 attendees. The society publishes the medical journal Blood, the most cited peer-reviewed publication in the field, which is available weekly in print and online, as well as the newly launched, online, peer-reviewed open-access journal, Blood Advances.

Modified Lenalidomide, Bortezomib, and Dexamethasone (RVD-lite) Regimen for Transplant-Ineligible Patients with Newly Diagnosed MM

ASH 2015 – Multiple Myeloma

Modification of the current treatment regimen of RVD to “RVD-lite” provided better tolerability and enhanced clinical benefits in transplant-ineligible patients and proved to be particularly manageable in older populations, even with a wide variety of performance statuses at the beginning of the study. Read More ›

Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma

ASH 2015 – Multiple Myeloma

ASH 2015 – Leukemia

ASH 2015 – Multiple Myeloma

Researchers presented 2-year follow-up safety and efficacy results of a phase 2 open-label study that compared the efficacy and safety of combination therapy with the anti-SLAM7 monoclonal antibody elotuzumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone alone in patients with relapsed/refractory multiple myeloma (RRMM). Read More ›

Lenalidomide/Dexamethasone versus Bortezomib/Lenalidomide/Dexamethasone in Newly Diagnosed Multiple Myeloma: Results of the Phase 3 SWOG S0777 Trial

ASH 2015 – Multiple Myeloma

Researchers report the results of a phase 2 study evaluating the tolerability and long-term outcomes using a combination of ixazomib plus cyclophosphamide and low-dose dexamethasone in newly diagnosed multiple myeloma (MM) patients who are not eligible for transplant. Read More ›

Long-Term Follow-Up of the HOVON-65/GMMG-HD4 Trial of Bortezomib Induction and Maintenance in Patients with Newly Diagnosed MM

ASH 2015 – Multiple Myeloma

Researchers report the significant and lasting improvement in progression-free survival and overall survival in patients treated with bortezomib. A subgroup analysis identified bortezomib to have an effect on the high-risk effects of del(17p) and renal impairment on survival. Read More ›

Randomized Phase 2 Study of the All-Oral Combination of Ixazomib plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Transplant-Ineligible Newly Diagnosed Multiple Myeloma

ASH 2015 – Multiple Myeloma

ASH 2015 – Leukemia

American Society of Hematology (ASH)

Page 32 of 44